Therapeutic potential of sulindac against ischemia-reperfusion-induced myocardial infarction in Diabetic and nondiabetic rats

Experimental and Clinical Cardiology

Volumn 13, Issue 2, 2008, Pages 66-70

  Annapurna, Akula ^a   Challa, Siva Reddy ^a   Prakash, Gomedhikam J ^a   Viswanath, Routhu Kasi ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

Cardioprotection; Diabetes; Polyol pathway; Reperfusion injury; Sulindac

Indexed keywords

ALDEHYDE REDUCTASE; IDITOL DEHYDROGENASE; LIPID PEROXIDE; STREPTOZOCIN; SULINDAC; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DIABETES MELLITUS; DRUG EFFICACY; ELECTROCARDIOGRAPHY MONITORING; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; REPERFUSION INJURY; SPECTROPHOTOMETRY; STREPTOZOCIN DIABETES; TISSUE LEVEL;

EID: 45749121534     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Stone GW, Grines CL, Browne KF, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol 1995;25:370-7.
2. Lehto S, Pyörälä K, Miettinen H, et al. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. J Intern Med 1994:236:291-7.
3. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801-13.
4. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987;316:599-606.
5. Roy TM, Broadstone VL, Peterson HR, et al. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus. Diabetes Res Clin Pract 1990;10:91-7.
6. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-9.
7. Xia P, Kramer RM, King GL. Identification of the mechanism for the inhibition of Na+,K(+)-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest 1995;96:733-40.
8. Parry GJ, Kozu H. Piroxicam may reduce the rate of progression of experimental diabetic neuropathy. Neurology 1990;40:1446-9.
9. Zochodne DW, Ho LT. The influence of indomethacin and guanethidine on experimental streptozotocin diabetic neuropathy. Can J Neurol Sci 1992;19:433-41.
10. Krishna KM, Gopal GS, Chalam CR, et al. The influence of sulindac on diabetic cardiomyopathy: A non-invasive evaluation by Doppler echocardiography in streptozotocin-induced diabetic rats. Vascul Pharmacol 2005;43:91-100.
11. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 1997;46:292-300.
12. Ramasamy R, Trueblood N, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol 1998;275:H195-203.
13. Simpson PJ, Lucchesi BR. Free radicals and myocardial ischemia and reperfusion injury. J Lab Clin Med 1987;110:13-30.
14. Klein HH, Pich S, Bohle RM, et al. Antiinflammatory agent BW 755 C in ischemic reperfused porcine hearts. J Cardiovasc Pharmacol 1988;12:338-44.
15. O'Neill PG, Charlat ML, Kim HS, et al. Lipoxygenase inhibitor nafazatrom fails to attenuate postischaemic ventricular dysfunction. Cardiovasc Res 1987;21:755-60.
16. Fernandes E, Toste SA, Lima JL, Reis S. The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. Free Radic Biol Med 2003;35:1008-17.
17. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969;6:24-7.
18. Johnson G 3rd, Tsao P, Lefer AM. Synergism between superoxide dismutase and sodium nitrite in cardioprotection following ischemia and reperfusion. Am Heart J 1990;119:530-7.
19. Fishbein MC, Meerabaum S, Rit J. Early phase acute myocardial infarct size quntification: Validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981;101:593-600.
20. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976;15:212-6.
21. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
22. Ulrich HB. Methods of Enzymatic Analysis, 2nd edn. London: Verlag Chemie Weinheim, Academic Press Inc, 1974:569-73.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951;193:265-75.
24. Feuvray D, Lopaschuk GD. Controversies on the sensitivity of the diabetic heart to ischemic injury: The sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res 1997;34:113-20.
25. Lee SM, Schade SZ, Doughty CC. Aldose reductase, NADPH and NADP+ in normal, galactose-fed and diabetic rat lens. Biochim Biophys Acta 1985;841:247-53.
26. Tilton RG, Chang K, Nyengaard JR, Van den Enden M, Ido Y, Williamson JR. Inhibition of sorbitol dehydrogenase: Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes 1995;44:234-42.
27. Hwang YC, Bakr S, Ellery CA, Oates PJ, Ramasamy R. Sorbitol dehydrogenase: A novel target for adjunctive protection of ischemic myocardium. FASEB J 2003;17:2331-3.
28. Hwang YC, Kaneko M, Bakr S, et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 2004;18:1192-9.